What You Should Know:
– Rune Labs, a precision neurology company, announced a strategic $12M funding round, bringing its total to over $42 million. The round was led by Nexus NeuroTech Ventures, a new brain disorder fund, with participation from existing investors.
– This strategic partnership marks a significant step forward in Rune Labs’ mission to revolutionize Parkinson’s disease care through personalized data and cutting-edge technology.
Transforming Parkinson’s Care with Data and AI
Rune Labs’ innovative approach revolves around StrivePD, a comprehensive software ecosystem featuring:
– FDA-cleared Apple Watch integration: Tracks tremors and dyskinesia, providing patients with continuous insights into their symptoms.
– Personalized data dashboards: Offer patients and clinicians valuable data visualizations for informed decision-making.
– Actionable insights powered by AI: Rune Labs is at the forefront of using generative AI to deliver personalized recommendations for managing PD.
Building on Success and Embracing AI
Rune Labs’ achievements extend beyond StrivePD. The company’s StriveStudy platform facilitates clinical trials for promising new therapies, while partnerships with leading innovators like BlueRock Therapeutics and Aspen Neuroscience further strengthen its commitment to personalized care. Additionally, Rune Labs is actively exploring generative AI tools to deliver even more personalized insights to patients at scale.
“For too long, we’ve been waiting for a cure that never comes,” says Benjamin Stecher, Chair of Rune Labs’ Patient Advisory Board and a person living with Parkinson’s. “StrivePD has empowered me to understand my disease better and work with my doctor to manage it more effectively. I believe Rune Labs is on the right track to transform how we receive care and ultimately find a cure for Parkinson’s.”
A Brighter Future for Patients with PD
With its data-driven approach, cutting-edge partnerships, and unwavering commitment to patient empowerment, Rune Labs is on a mission to redefine PD care. This latest funding boost fuels their journey to develop AI-powered solutions that unlock personalized treatment plans, optimize clinical trials, and ultimately, bring hope to the millions living with this debilitating disease.
